← Markets

AbbVie Inc.

ABBV · NYSE

Market closed$254.49$0.100000 (+0.04%)After hours $254.25 · -0.09%

Key statistics

Previous close$254.39
Open$257.04
Day high$260.88
Day low$254.30
52-week high$261.64
52-week low$184.63
Market cap449.63B
Volume5.22M
Average volume7.15M
P/E ratio24.97
Forward P/E—
EPS10.19
Dividend yield+2.68%

Market context

Why it moved

AbbVie's stock surged today driven by a combination of multiple analyst price target upgrades — including BMO Capital Markets raising its target to $300 with an "outperform" rating — positive clinical trial outcomes for key post-Humira growth drivers Skyrizi and Rinvoq, and strong institutional buying ahead of the company's Q2 earnings report on July 31.

StocktwitsTradingkeyInquirerMorningstarInvesting.com

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026AbbVie closed essentially flat as a notable intraday rally faded, with shares pulling back from a session high of $260.88 after the European Commission approved Allergan Aesthetics' Boey botulinum toxin for frown lines — a product differentiated by its rapid onset and short duration. Analyst sentiment remains broadly constructive ahead of the July 31 Q2 earnings report, with William Blair reiterating a Buy and a Street consensus target near $273, though Citi's recent downgrade to Hold tempers near-term enthusiasm. Pipeline momentum from new regulatory submissions for RINVOQ in alopecia areata and a subcutaneous SKYRIZI option for Crohn's disease continues to reinforce confidence that AbbVie's immunology-led growth can sustain Humira biosimilar offsets.

0.0393

July 17, 2026AbbVie rose sharply, outperforming both the healthcare sector (XLV) and the broader S&P 500, as a wave of bullish analyst activity and pipeline momentum converged ahead of its July 31 Q2 earnings report. Multiple firms raised price targets in July — including BMO to $300, JP Morgan to $280, and Piper Sandler to $298 — with analysts highlighting strength in the immunology franchise as Skyrizi and Rinvoq continue to more than offset Humira biosimilar erosion. New regulatory filings for RINVOQ in severe alopecia areata and a subcutaneous SKYRIZI option in Crohn's disease reinforced confidence in the next growth wave, while a Citi downgrade to Hold (maintaining a $260 target) provided a modest counterweight. William Blair also maintained its Buy rating on the day, and the Street's consensus sits at Strong Buy with an average target near $273.

4.2358

July 16, 2026AbbVie closed modestly lower, slipping less than a quarter percent, as Citigroup downgraded the stock to Neutral while simultaneously raising its price target from $230 to $260 — a move suggesting the analyst sees limited near-term upside after recent appreciation. The cautious repositioning comes amid a broader healthcare sector rotation highlighted by UBS, which upgraded the sector as a key allocation focus alongside AI. AbbVie's underlying fundamentals remain compelling, with Skyrizi and Rinvoq posting 31% and 23% Q1 2026 growth respectively, full-year EPS guidance raised to $14.08–$14.28, and a fresh $1.73 quarterly dividend declared with an ex-date of July 15.

-0.2288

July 15, 2026AbbVie closed modestly lower, underperforming the broader market as healthcare sector headwinds weighed on sentiment ahead of a critical earnings week. The XLV healthcare ETF also declined on the day, with sector peers Abbott Labs falling over 3% on litigation and device concerns. UBS recently maintained its Neutral rating on AbbVie while raising its price target to $260, reflecting cautious optimism around the biopharma name. Morningstar highlighted biopharma as a sector opportunity even as the broader healthcare group faces a projected 9% Q2 earnings decline, amplified by macro pressures including Iran-driven oil volatility and a Fed leaning hawkish.

-1.2984

July 14, 2026AbbVie closed essentially flat as a wave of bullish analyst activity dominated the narrative ahead of Q2 earnings. BMO Capital raised its price target to $300 (from $258), BofA upgraded to Buy with a $276 target, and Wells Fargo reiterated Buy at $295, all citing Skyrizi's durable revenue performance despite competition from oral rival Icotyde. The broader market weighed on healthcare as U.S.-Iran tensions sent oil prices surging 4-5% and pressured equities, with the XLV healthcare ETF also closing lower.

-0.0322

July 11, 2026AbbVie edged lower on Friday, underperforming the broader S&P 500 which closed modestly higher, as a wave of analyst price target increases failed to offset broader healthcare sector softness. RBC Capital, Wells Fargo, and BofA Securities all raised their price targets on AbbVie to $280, $295, and $276, respectively, with RBC noting that investor sentiment has shifted significantly following the recent Apogee deal, which addresses a key overhang for the stock. With Q2 results due July 31 and expectations largely in line, investors appear to be in a wait-and-see mode ahead of earnings. In after-hours trading, shares recovered nearly all of the session's losses.

-0.7323

July 10, 2026AbbVie closed modestly lower, pressured by the broader market selloff tied to renewed U.S.-Iran hostilities and surging oil prices that reignited inflation fears. Despite the macro headwinds, company-specific catalysts remain constructive: JPMorgan raised its price target to $280 (from $260) maintaining Overweight, and Guggenheim lifted its target to $261, reaffirming Buy. Adding to the positive backdrop, Europe's approval of TEPKINLY + R2 for relapsed/refractory follicular lymphoma last week—showing a 79% reduction in disease progression risk—extended AbbVie's oncology reach. A separate national security inquiry by U.S. lawmakers over China clinical trial data practices added a modest overhang.

-1.1197

July 9, 2026AbbVie closed modestly lower amid a broad market risk-off selloff driven by President Trump declaring the U.S.-Iran ceasefire 'over,' which sent oil prices surging and weighed on equities broadly. The healthcare sector (XLV) also pulled back on the day, though AbbVie's decline was relatively contained given positive catalysts: Morgan Stanley nudged its price target to $279 (maintaining Overweight), and the European Commission recently granted marketing authorization for TEPKINLY + R2 in relapsed/refractory follicular lymphoma—a first-in-class, chemotherapy-free bispecific regimen showing a 79% reduction in disease progression risk. In after-hours trading, shares edged back toward $254.

-0.8011

Seeking Alpha · July 17, 2026AbbVie granted EU nod for Boey anti-wrinkle therapy (ABBV:NYSE)TradingView · July 17, 2026Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?qz.com · July 17, 2026Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales GrowthSimply Wall Street · July 17, 2026AbbVie (ABBV) Boey Approval Puts Its Growth Story And Valuation Back In FocusAmerican Hospital Association · July 15, 2026AHA urges court to reject AbbVie bid to change 340B program rulesInvestor's Business Daily · June 22, 2026AbbVie Goes On The Offensive With $10.9 Billion TakeoverInvesting.com · April 29, 2026Earnings call transcript: AbbVie Q1 2026 beats expectations, stock dipsPR Newswire · October 31, 2025AbbVie Reports Third-Quarter 2025 Financial Results
Benzinga · July 17, 2026Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today
Mt Newswire · July 17, 2026AbbVie's Allergan Aesthetics Says Boey Wrinkle Treatment Wins EU Approval
Benzinga · July 17, 2026Allergan Aesthetics' Boey Receives European Commission Approval To Treat Moderate To Severe Lines Between The Eyebrows
Benzinga · July 15, 2026Citigroup Maintains Neutral on AbbVie, Raises Price Target to $260
Mt Newswire · July 15, 2026Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating
Benzinga · July 13, 2026UBS Maintains Neutral on AbbVie, Raises Price Target to $260
Mt Newswire · July 13, 2026BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating
Mt Newswire · July 13, 2026UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating

Peers

S&P 500SPX · $7,457.69-1.01%Eli Lilly and CompanyLLY · $1,179.09+0.85%Johnson & JohnsonJNJ · $253.04+1.23%Pfizer Inc.PFE · $25.05-0.36%Merck & Co., Inc.MRK · $127.50-0.10%Amgen Inc.AMGN · $366.29-1.42%Bristol-Myers Squibb CompanyBMY · $60.74+0.38%Gilead Sciences, Inc.GILD · $134.28-1.48%Biogen Inc.BIIB · $205.99-1.40%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%AstraZeneca PLCAZN · $168.90-0.23%Roche Holding AGRO.SW · 339.60+0.83%